DERMATITIS ATOPIC

This large, late-stage study tested an injectable drug called amlitelimab for people aged 12 and older with moderate-to-severe atopic dermatitis (eczema) that wasn't well-controlled by creams. Over 600 participants were randomly assigned to receive either the drug or a placebo in…

This study tested the long-term safety and effectiveness of an oral medication called abrocitinib for people aged 12 and older with moderate to severe eczema (atopic dermatitis). Over 3,100 participants who had completed a previous related trial took either a 100 mg or 200 mg pil…

This study tested if a new drug for moderate-to-severe eczema (amlitelimab) changes how well the body responds to common vaccines. Researchers compared vaccine antibody levels in 224 adults who received either the drug or a placebo along with tetanus and pneumonia shots. The main…

This large, late-stage study tested an investigational drug called amlitelimab, given as an injection under the skin, for people aged 12 and older with moderate-to-severe atopic dermatitis (eczema). The goal was to see if adding amlitelimab to standard topical creams could better…

This study tested a new injectable drug called 611 in Chinese adults with moderate to severe atopic dermatitis (eczema). The goal was to see if the drug could safely reduce the severity of skin rashes and itching over a year of treatment. Researchers compared the drug's effects a…

This study tested an investigational drug called SCD-044 to see if it could improve the skin and reduce itching in adults with moderate to severe eczema. For 16 weeks, 250 participants received either the drug or a placebo (an inactive substance) without knowing which one they go…

This large, late-stage study tested a new injectable drug called amlitelimab for people aged 12 and older with moderate-to-severe atopic dermatitis (eczema) that wasn't well-controlled by creams. Nearly 600 participants were randomly assigned to receive either the drug or a place…

This study looked at whether the medication dupilumab helps repair the skin's protective barrier in people with moderate-to-severe eczema. It involved 44 Chinese patients who received dupilumab for 16 weeks. Researchers measured how well the skin held moisture before and after ge…

This early-stage study tested the safety and effects of an experimental drug called BMS-986326 in adults with moderate-to-severe eczema. Researchers gave 64 participants either the drug or a placebo to check for side effects and measure how the drug behaves in the body. The main …

This study tested an investigational drug called BI 655130, given by IV infusion, to see if it is safe and effective for adults with moderate to severe atopic dermatitis (eczema). It compared the drug to a placebo in 51 patients over 16 weeks. The main goal was to see how much th…

This study aimed to understand how the medication dupilumab affects the skin's protective barrier in children with moderate to severe eczema (atopic dermatitis). It involved 41 children who received the drug, and researchers used a special tape-stripping method to measure how wel…

This study aimed to understand how the approved eczema medication dupilumab works to reduce chronic itching. Researchers took small skin samples from 54 adults with moderate-to-severe eczema before and after treatment to see if the drug changed nerve fibers in the skin. The goal …